Patent Office Rules in Neuralstem's Favor in Dispute with StemCells,
Inc.
September 19, 2007: 10:02 AM EST
ROCKVILLE, Md., Sept. 19 /PRNewswire-
Neuralstem, Inc. , announced today that it has received notice that
the United States Patent and Trademark Office (USPTO) has issued its
first ruling in the reexamination of the four StemCells, Inc. patents
requested by Neuralstem.
(Logo: http://www.newscom.
"The Patent Office has rejected on multiple grounds all of the claims
in all four of StemCells' patents that it examined," said Neuralstem
President & CEO, Richard Garr. "In accepting the reexamination months
ago," Garr explained, "the Patent Office was only ruling that, on its
face, there was enough evidence to disallow the claims. Now after
careful examination, the Patent Office has issued an official
rejection of each of the claims in all four of the patents that
StemCells attempted to assert against Neuralstem in its law suit.
Importantly the Patent Office is rejecting the StemCells patents
based on additional prior art references that were not even the focus
of our reexamination request. We are pleased but certainly not
surprised by the Patent Office's rejection of all the claims in all
the relevant StemCells patents," Garr went on to say. "We believe
that the Patent Office has now correctly found that these claims
should never have been issued in the first place."
About Neuralstem
Neuralstem's patent-protected technology enables, for the first time,
the ability to produce neural stem cells of the human brain and
spinal cord in commercial quantities, and the ability to control the
differentiation of these cells into mature, physiologically relevant
human neurons and glia. The Company expects that its first
Investigational New Drug (IND) application will be for the treatment
of Ischemic Paraplegia, a form of paraplegia that sometimes results
from the surgery to repair aortic aneurysms and for which there is no
effective treatment The Company hopes to submit its initial IND
application to the FDA and begin its first human trial during
calendar year 2007.
Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Ischemic Paraplegia,
Traumatic Spinal Cord Injury, ALS, and Parkinson's disease. The
company's cells recently extended the life of rats with ALS (Lou
Gehrig's disease) in a paper published in the journal
TRANSPLANTATION, and were deemed viable for continued work in
neurodegenerative spinal conditions. Neuralstem cells also reversed
paralysis in rats with Ischemic Spastic Paraplegia, a form of
paralysis that can result from the surgery to repair aortic
aneurysms, as reported in NEUROSCIENCE (http://www.neurosci
ibro.com/). The company has also developed immortalized human neural
stem cells for in-vitro use in drug development for the academic and
pharmaceutical markets. For further information, please visit
http://www.neuralst
Cautionary Statement Regarding Forward Looking Information
This presentation may contain forward-looking information about
Neuralstem, Inc. which is intended to be covered by the safe harbor
for forward-looking statements provided by the Private Securities
Litigation Reform Act of 1995. Forward- looking statements are
statements that are not historical facts. These statements can be
identified by the use of forward- looking terminology such
as "believe," "expect," "may," "will," "should," "project," "plan," "s
eek," "intend," or "anticipate" or the negative thereof or comparable
terminology, and include discussions of strategy, and statements
about industry trends and Neuralstem's future performance, operations
and products. This and other "Risk Factors" contained in Neuralstem's
public filings with the SEC should be read in connection with this
release. For further information on Neuralstem, please review the
company's filings with the SEC including its Annual Report filed on
Form 10-KSB for the period ended December 31, 2006, as well as the
company's subsequent filings.
http://money.
-1.htm
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
